Chikungunya Vaccine Safety and Immune Response Study
Part of Infections clinical trials.
This study tests a new vaccine to protect against chikungunya virus, a disease spread by mosquitoes that causes fever and joint pain. The study measures how well your immune system responds to the vaccine and tracks any side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 12 and 65 years old and in good overall health
- Agree to keep a diary of any symptoms and complete all study visits
- If you can have children, agree to use effective birth control for at least 3 months after your last vaccine dose
- Agree to let researchers store a blood sample for chikungunya research
- Not have had certain conditions like rheumatoid arthritis, diabetes, neurological diseases, or cancer
- Not be pregnant, breastfeeding, or recently vaccinated (within 30 days)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental vaccine designed to protect against chikungunya, a mosquito-borne virus that causes fever and joint pain. The trial will evaluate the vaccine's safety and immune response in healthy adults.
This trial tests an experimental chikungunya vaccine (made from a virus-like particle) to see if it prevents the disease. It is for healthy teens and adults who have not had chikungunya before.
This study tests how well the chikungunya vaccine (IXCHIQ) triggers an immune response in people aged 12 to 59. It is a phase 2 trial to see if the vaccine produces a good antibody response.
This study looks at how well the VLA1553 vaccine prevents chikungunya disease in parts of Brazil where the vaccine is being offered as part of a pilot program. If you live in one of those areas and have had symptoms that might be chikungunya, this study will use your health records and blood tests to check how effective the vaccine is.
This trial tests whether giving the dengue and chikungunya vaccines together is as safe and effective as giving them separately. If you are a healthy adult, you may be able to help find a more convenient way to protect against these diseases.
This study follows pregnant women who received the VLA1553 vaccine (for chikungunya) to see how it affects them and their babies. It compares them to pregnant women who received a different vaccine approved during pregnancy.
Hear when a new Active Immunisation for Chikungunya Virus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.